CDK6 and leukemia: While suppressing CDK6 expression alone exerts anti-leukemia effects in our pre-clinical studies in mice injected with primary Ph+ ALL cells, treatment with PROTAC YX-2-107 may not achieve a long-lasting therapeutic response.